| Literature DB >> 32867101 |
Feifei Li1,2, Bin Liu3, Tong Li1, Qianwen Wu1, Zhiyong Xu4, Yuhao Gu1, Wen Li1, Penglong Wang1, Tao Ma1, Haimin Lei1,2.
Abstract
Glycyrrhizae Radix et Rhizoma is regarded as one of the most popular and commonly used herbal medicines and has been used in traditional Chinese medicine (TCM) prescriptions for over 2000 years. Pentacyclic triterpene saponins are common secondary metabolites in these plants, which are synthesized via the isoprenoid pathway to produce a hydrophobic triterpenoid aglycone containing a hydrophilic sugar chain. This paper systematically summarizes the chemical structures of triterpene saponins in Glycyrrhizae Radix et Rhizoma and reviews and updates their main biological activities studies. Furthermore, the solubilization characteristics, influences, and mechanisms of Glycyrrhizae Radix et Rhizoma are elaborated. Solubilization of the triterpene saponins from Glycyrrhizae Radix et Rhizoma occurs because they contain the nonpolar sapogenin and water-soluble sidechain. The possible factors affecting the solubilization of Glycyrrhizae Radix et Rhizoma are mainly other crude drugs and the pH of the decoction. Triterpene saponins represented by glycyrrhizin from Glycyrrhizae Radix et Rhizoma characteristically form micelles due to amphiphilicity, which makes solubilization possible. This overview provides guidance regarding a better understanding of GlycyrrhizaeRadix et Rhizoma and its TCM compatibility, alongside a theoretical basis for the further development and utilization of Glycyrrhizae Radix et Rhizoma.Entities:
Keywords: Glycyrrhizae Radix et Rhizoma; biological activities; glycyrrhizin; solubilization; triterpene saponins
Mesh:
Substances:
Year: 2020 PMID: 32867101 PMCID: PMC7503449 DOI: 10.3390/molecules25173904
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Triterpene saponins in G. uralensis.
Figure 2Triterpene saponins in G. glabra.
Figure 3Triterpene saponins in G. inflata.
Information on triterpene saponins in glycyrrhiza.
| No. | Compound | Origin | References |
|---|---|---|---|
|
| glycyrrhizin (glycyrrhizic acid, uralsaponin A or 18β-glycyrrhizic acid) | a,b,c | [ |
|
| uralsaponin B | a,b | [ |
|
| licorice-saponin A3 | a,c | [ |
|
| licorice-saponin B2 | a,b | [ |
|
| licorice-saponin C2 | a,b | [ |
|
| licorice-saponin D3 | a | [ |
|
| licorice-saponin E2 | a,c | [ |
|
| licorice-saponin F3 | a | [ |
|
| licorice-saponin G2 | a,b,c | [ |
|
| licorice-saponin H2 | a,b | [ |
|
| licorice-saponin J2 | a,b | [ |
|
| licorice-saponin K2 | a,b | [ |
|
| licorice-saponin L3 | a | [ |
|
| 18α-glycyrrhizic acid | a,b | [ |
|
| apioglycyrrhizin | b,c | [ |
|
| araboglycyrrhizin | a,b,c | [ |
|
| 22β-acetoxylglycyrrhizin | a,c | [ |
|
| 3β- | a | [ |
|
| 3β- | a | [ |
|
| uralsaponin C | a | [ |
|
| uralsaponin D | a,c | [ |
|
| uralsaponin E | a | [ |
|
| uralsaponin F | a | [ |
|
| 3- | a | [ |
|
| licorice-saponin M3 | a,b | [ |
|
| licorice-saponin N4 | a,b | [ |
|
| licorice-saponin O4 | b | [ |
|
| uralsaponin M | a | [ |
|
| uralsaponin N | a | [ |
|
| uralsaponin O | a | [ |
|
| uralsaponin P | a | [ |
|
| uralsaponin Q | a | [ |
|
| uralsaponin R | a | [ |
|
| uralsaponin S | a | [ |
|
| uralsaponin U | a | [ |
|
| uralsaponin V | a,b | [ |
|
| uralsaponin W | a | [ |
|
| uralsaponin X | a | [ |
|
| uralsaponin Y | a | [ |
|
| 22β-acetoxyl-glycyrrhaldehyde | a,c | [ |
|
| 3- | a,b | [ |
|
| 3- | a | [ |
|
| licorice-saponin P2 | c | [ |
|
| licorice-saponin Q2 | c | [ |
|
| macedonoside A | b,c | [ |
|
| 24-hydroxy-licorice-saponin E2 | c | [ |
|
| macedonoside E | a | [ |
|
| 22β-acetyl-uralsaponin C | a | [ |
|
| licorice saponin M1 | b | [ |
|
| licorice saponin M2 | b | [ |
|
| licorice saponin M3 | b | [ |
|
| licorice saponin M4 | b | [ |
|
| 30-hydroxyglycyrrhizin | b | [ |
|
| glycyrrhizin-20-methanoate | b | [ |
|
| 24-hydroxyglucoglycyrrhizin | b | [ |
|
| rhaoglycyrrhizin | b | [ |
|
| 11-deoxorhaoglycyrrhizin | b | [ |
|
| rhaoglucoglycyrrhizin | b | [ |
|
| rhaogalactoglycyrrhizin | b | [ |
|
| 11-deoxo-20α-glycyrrhizin | b | [ |
|
| 20α-galacturonoylglycyrrhizin | b | [ |
|
| 20α-rhaoglycyrrhizin | b | [ |
|
| glyuralsaponin A | a | [ |
|
| glyuralsaponin B | a | [ |
|
| glyuralsaponin C | a | [ |
|
| glyuralsaponin D | a | [ |
|
| glyuralsaponin E | a | [ |
|
| glyuralsaponin F | a | [ |
|
| glyuralsaponin G | a | [ |
|
| glyuralsaponin H | a | [ |
|
| glabasaponin A | b | [ |
|
| glabasaponin B | b | [ |
|
| glabasaponin C | b | [ |
|
| glabasaponin D | b | [ |
|
| glabasaponin E | b | [ |
|
| glabasaponin F | b | [ |
|
| glabasaponin G | b | [ |
a, G. uralensis Fisch.; b, G. glabra L.; c, G. inflate Bat.
Summary of the biological activities conducted with triterpene saponins in glycyrrhiza 1.
| No. | Compound | Activity | References | ||
|---|---|---|---|---|---|
| Property | Method | Major Findings | |||
|
| glycyrrhizin | Hepatoprotective activities | In vitro—primary rat hepatocytes injured by | Lower alanine aminotransaminase (ALT) and aspartate aminotransaminase (AST) levels | [ |
| PLA2 inhibitory potency | IC50 = 9.3 μM | [ | |||
| In vitro—primary cultured rat hepatocytes induced by CCl4 | Prevent soluble enzyme release | [ | |||
| In vitro—PLC/PRF/5 cells | Modify the expression of hepatitis B virus (HBV)-related antigens on the hepatocytes and suppress sialylation of HBsAg | [ | |||
| In vivo—BALB/c mice | Suppress increases in AST and ALT, inhibit inducible nitric oxide synthase (iNOS) mRNA expression, and reduce protein and cell infiltration and the degeneration of hepatocytes | [ | |||
| In vivo—ICR mice | Alleviate CCl4-induced liver injury | [ | |||
| In vivo—Sprague Dawley rats | Exhibit protective effect on retrorsine-induced liver damage | [ | |||
| In vivo—Wistar rats | Provide partial protection of the liver against ischemia-reperfusion damage | [ | |||
| In vivo—Wistar rats | Protect against NTiO2-induced hepatotoxicity | [ | |||
| Anti-inflammatory activities | In vitro—lipopolysaccharide (LPS)-stimulated mouse endometrial epithelial cells (MEEC) | Inhibit LPS-induced inflammatory response by inhibiting TLR4 signaling pathway | [ | ||
| In vitro—neutrophil | Inhibit reactive oxygen species (ROS) generation by neutrophils | [ | |||
| In vivo—Sprague Dawley rats | Inhibit HMGB1 expression and subsequent production of inflammatory cytokines to prevent cerebral vasospasm (CVS) following subarachnoid hemorrhage (SAH) | [ | |||
| In vivo—SD rats | Alleviate brain injury after diffuse axonal injury (DAI) via its anti-inflammatory effects | [ | |||
| Antimicrobial and antiviral activities | In vitro | Inhibit varicella zoster virus (VZV) | [ | ||
| In vitro | Inhibit severe acute respiratory syndrome coronavirus (SARS-CoV) replication | [ | |||
| In vitro | Inhibited influenza A virus (IAV) uptake into the cell | [ | |||
| In vitro | Reduce the severity of an infection with COVID-19 at the two stages of the COVID-19 induced disease process, 1. To block the number of entry points and 2. provide an ACE2 independent anti-inflammatory mechanism. | [ | |||
| The commercial NA inhibitory screening kit | Possess moderate influenza NA inhibitory activity | [ | |||
| Cytotoxic and antitumor activities | In vivo—tumor-bearing mice | Reduce expression of TxAS, as well as proliferating cell nuclear antigen (PCNA), and rescue liver and kidney damage | [ | ||
| In vitro—HepG2 | Display protective effects against Aflatoxin B1 (AFB1)-induced cytotoxicity | [ | |||
| Other activities | - | 1. Possess immunomodulatory, neuroprotective effects, and antioxidant activities; 2. Bronchitis, peptic ulcers, skin diseases, and oral diseases; 3. Allergic rhinitis | [ | ||
|
| licorice-saponin A3 | Antimicrobial and antiviral activities | The commercial NA inhibitory screening kit | Possess moderate influenza NA inhibitory activity | [ |
|
| licorice-saponin G2 | Hepatoprotective activities | In vitro—primary rat hepatocytes injured by | Lower ALT and AST levels | [ |
| PLA2 inhibitory potency | IC50 = 16.9 μM | [ | |||
| Antimicrobial and antiviral activities | The commercial NA inhibitory screening kit | Possess moderate influenza NA inhibitory activity | [ | ||
|
| 22β-acetoxylglycyrrhizin | Hepatoprotective activities | In vitro—primary rat hepatocytes injured by | Lower ALT and AST levels | [ |
| PLA2 inhibitory potency | IC50 = 27.1 μM | [ | |||
| Antimicrobial and antiviral activities | In vitro—Madin–Darby canine kidney (MDCK) cells | Inhibit influenza virus A/WSN/33 (H1N1) | [ | ||
| The commercial NA inhibitory screening kit | Possess moderate influenza NA inhibitory activity | [ | |||
|
| uralsaponin D | Hepatoprotective activities | PLA2 inhibitory potency | IC50 = 32.2 μM | [ |
|
| licorice-saponin M3(uralsaponin T) | Antimicrobial and antiviral activities | In vitro—MDCK cells | Inhibit influenza virus A/WSN/33 (H1N1) | [ |
| The commercial NA inhibitory screening kit | Possess moderate influenza NA inhibitory activity | [ | |||
|
| uralsaponins M–Y | Antimicrobial and antiviral activities | In vitro—MDCK cells | Uralsaponin M (28) and uralsaponin S (34) exhibited inhibitory activities against influenza virus A/WSN/33 (H1N1) | [ |
|
| licorice-saponin Q2 (44) | Hepatoprotective activities | In vitro—primary rat hepatocytes injured by | Lower ALT and AST levels | [ |
| PLA2 inhibitory potency | IC50 = 3.6 μM (44) and 6.9 μM (45) | [ | |||
|
| glyuralsaponins A–H | Hepatoprotective activities | MDA colorimetric assay | Glyuralsaponin B (64) and glyuralsaponin H (70) exhibited moderate antioxidant activities against Fe2+/cysteine-induced liver microsomal lipid peroxidation | [ |
1, Columns 1 and 2 is the same in Table 1. It should be noted that the empty rows with triterpene saponins are grouped together or not listed in Table 2.
Summary on solubilization of glycyrrhiza and GL (1).
| No. | Name | TCM Formulae/TCM/Component | Characteristics | Major Findings | References |
|---|---|---|---|---|---|
|
| glycyrrhiza | sijunzi decoction, huangqi dazao decoction, baishao gancao decoction | Glycyrrhiza has solubilization effects in three traditional Chinese medicine (TCM) formulae | The solubilizing components in glycyrrhiza are triterpene saponins | [ |
|
| ephedra | The contents of GL (1), ephedrine, and methephedrine et al. all increase | - | [ | |
|
| epimedium | Icariin in epimedium increases | - | [ | |
|
| curcuma longa | The extractive rate of curcumin double | GL (1) is the main surfactant | [ | |
|
| codonopsis, poria, atractylodes, | Glycyrrhiza can increase the contents of active ingredients in these TCM | GL (1) is the main surfactant | [ | |
|
|
| No solubilization effects | One of the possible factors affecting the solubilization is some other crude drugs | [ | |
|
| GL (1) | saikosaponin-a | The contents of saikosaponin-a increase | Solubilizing effect is due to GL (1) | [ |
|
| Ben Lamge granules | The solubility of Ben Lamge granules increases | 1. The surface tension of GL (1) decreases; | [ | |
|
| baicalin | The dissolution rate of baicalin increases | - | [ | |
|
| pueraria | The solubility of pueraria increases | Another possible factor affecting the solubilization is the pH value of the solution | [ | |
|
| pachymic acid | Increase the solubility of pachymic acid | Improve the bioavailability of pachymic acid | [ | |
|
| Puerarin-glycyrrhizic acid dispersible tablets | Improve the dissolution of puerarin | GL (1) possesses solubilization effect | [ |